The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani

BACKGROUND: New drugs are needed for leishmaniasis because current treatments such as pentavalent antimonials are toxic and require prolonged administration, leading to poor patient compliance. Ibrutinib is an anticancer drug known to modulate T-helper type 1 (Th1)/Th2 responses and has the potentia...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Infect Dis
Huvudupphovsmän: Varikuti, Sanjay, Volpedo, Greta, Saljoughian, Noushin, Hamza, Omar M, Halsey, Gregory, Ryan, Nathan M, Sedmak, Bren E, Seidler, Gabriella R, Papenfuss, Tracey L, Oghumu, Steve, Satoskar, Abhay R
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2019
Ämnen:
Major Articles and Brief Reports
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784510/
https://ncbi.nlm.nih.gov/pubmed/30239895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy552
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk